drugset / Trial / NCT04958876
Study to Evaluate the Safety of SP-104
RandomizedCrossoverQuadruple-blindTreatment
Summary
Evaluate the safety and tolerability of 3-day repeat-dose of SP-104 compared to naltrexone hydrochloride immediate release.
Timeline
- Start
- 2021-10-04
- Primary completion
- 2021-12-20
- Completion
- 2021-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dronabinol | Other / unclassified | — | Oral |
| Subject | Naltrexone | Small molecule | — | Oral |
Indications
No indication recorded.